NBIX
Neurocrine Biosciences
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: NBIX
- PE Ratio
As of Nov 11, 2026, the NBIX stock has a PE ratio of 25.02. The calculation is based on the latest EPS of $6.97 and the stock price of $174.41 per share. An increase of 7% has been observed in the PE ratio compared to its average of 23.3 of the last four quarters.
NBIX PE ratio history
The mean historical PE ratio of Neurocrine Biosciences over the last nine years is 149.22. The current 25.02 P/E ratio is 83% lower than the historical average. Looking back at the last nine years, NBIX's PE ratio peaked in the Sep 2018 quarter at 1,229.5, with a price of $122.95 and an EPS of $0.1. The Mar 2026 quarter marked the lowest point at 19.63, with a price of $131.74 and an EPS of $6.71.
Neurocrine Biosciences PE ratio by year
Maximum annual increase: 648% in 2012
Maximum annual decrease: -91.86% in 2020
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 29.49 | -26.55% | $141.83 | $4.81 |
| 2024 | 40.15 | -21.99% | $136.5 | $3.4 |
| 2023 | 51.47 | -30.62% | $131.76 | $2.56 |
| 2022 | 74.19 | -17.24% | $119.44 | $1.61 |
| 2021 | 89.65 | 309.73% | $85.17 | $0.95 |
| 2020 | 21.88 | -91.86% | $95.85 | $4.38 |
| 2019 | 268.73 | -13.45% | $107.49 | $0.4 |
| 2018 | 310.48 | N/A | $71.41 | $0.23 |
| 2017 | N/A | N/A | $77.59 | -$1.62 |
| 2016 | N/A | N/A | $38.7 | -$1.63 |
| 2015 | N/A | N/A | $56.57 | -$1.05 |
| 2014 | N/A | N/A | $22.34 | -$0.81 |
| 2013 | N/A | N/A | $9.34 | -$0.69 |
| 2012 | 93.5 | 648% | $7.48 | $0.08 |
| 2011 | 12.5 | N/A | $8.5 | $0.68 |
Neurocrine Biosciences PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Sep 2026 | 20.35 | -14.89% | $141.84 | $6.97 |
| Jun 2026 | 23.91 | 21.8% | $168.54 | $7.05 |
| Mar 2026 | 19.63 | -33.44% | $131.74 | $6.71 |
| Dec 2025 | 29.49 | -9.46% | $141.83 | $4.81 |
| Sep 2025 | 32.57 | -9.83% | $140.38 | $4.31 |
| Jun 2025 | 36.12 | -1.04% | $125.69 | $3.48 |
| Mar 2025 | 36.5 | -9.09% | $110.6 | $3.03 |
| Dec 2024 | 40.15 | 34.51% | $136.5 | $3.4 |
| Sep 2024 | 29.85 | -25.64% | $115.22 | $3.86 |
| Jun 2024 | 40.14 | 9.73% | $137.67 | $3.43 |
| Mar 2024 | 36.58 | -28.93% | $137.92 | $3.77 |
| Dec 2023 | 51.47 | -10.33% | $131.76 | $2.56 |
| Sep 2023 | 57.4 | 11.39% | $112.5 | $1.96 |
| Jun 2023 | 51.53 | -65.89% | $94.3 | $1.83 |
| Mar 2023 | 151.07 | 103.63% | $101.22 | $0.67 |
NBIX Price vs fair value
NBIX average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
NBIX's current PE ratio is lower than its 3, 5 and 10-year averages.
PE comparison
Neurocrine Biosciences's price to earnings (P/E) of 25.02 is higher than the Healthcare sector and the industry average but lower than its peers average. But in comparison with the Healthcare sector average of 24.8, Neurocrine Biosciences's price to earnings (P/E) is only 0.9% higher.
NBIX PE vs peers
Frequently asked questions
What is Neurocrine Biosciences's PE ratio?
The price to earnings ratio for NBIX stock is 25.02 as of Nov 11, 2026.
What is the 3-year average PE ratio for Neurocrine Biosciences (NBIX)?
Over the last 3 years, the average price to earnings ratio for NBIX stock is 33.06.
What is the 5-year average PE ratio for Neurocrine Biosciences (NBIX)?
Over the last 5 years, the average price to earnings ratio for NBIX stock is 93.4.
What is the highest PE ratio for NBIX?
The highest quarterly PE ratio in the last nine years has been 1,229.5 and it was in the Sep 2018 quarter.
How does the current PE ratio for NBIX compare to its historical average?
NBIX's current price to earnings ratio is 83% below its 9-year historical average.
How is NBIX's PE ratio calculated (Neurocrine Biosciences PE ratio formula)?
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Nov 11, 2026), Neurocrine Biosciences's share price is $174.41. The company's earnings per share for the trailing twelve months (TTM) ending Sep 2026 is $6.97. Therefore, Neurocrine Biosciences's PE ratio for today is 25.02. PE RATIO(25.02) = STOCK PRICE($174.41) / TTM EPS($6.97)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.